Get to know our clinical trials
Clinical trial for perioperative treatment with durvalumab plus tremelimumab in patients with resectable hepatocellular carcinoma (HCC)
THE MAIN GOAL OF THIS STUDY, WHICH INCLUDES RESEARCH, IS TO DETERMINE WHETHER THE NEW CANCER DRUG DURVALUMAB GIVEN WITH TREMELIMUMAB IS SAFE BEFORE SURGERY. DOCTORS ALSO WANT TO SEE IF THE STUDY DRUGS CAUSE ANY DELAYS IN SURGERY DUE TO SIDE EFFECTS THAT PARTICIPANTS MAY EXPERIENCE. DOCTORS WILL ALSO ANALYZE THE EFFECT THAT THE STUDY DRUGS HAVE ON THE TUMOR AND WHETHER THE TUMOR RECURS AFTER THE COMBINATION OF THE STUDY DRUGS AND SURGERY.
Technical Summary
- PHASE II CLINICAL TRIAL FOR PERIOPERATIVE TREATMENT WITH DURVALUMAB PLUS TREMELIMUMAB IN PATIENTS WITH RESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
- Code EudraCT: 2023-508863-59-00
- Protocol number: OZUHN-007
- Promoter: Univesity Health network
- Molecule/Drug: Durvalumab Plus Tremelimumab
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.